LINC01255: A Long Intergenic Non-Protein Coding RNA (G101927433)

Target Name: LINC01255

NCBI ID: G101927433

LINC01255

Other Name(s): long intergenic non-protein coding RNA 1255 | Long intergenic non-protein coding RNA 1255, transcript variant 1

LINC01255: A Long Intergenic Non-Protein Coding RNA

LINC01255 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique structure, which consists of a series of introns and exons that do not encode any protein sequences. Despite its non-protein nature, LINC01255 has been shown to play a critical role in various cellular processes, including cell growth, development, and disease.

Disease-Related Role of LINC01255

LINC01255 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most significant findings related to LINC01255 is its involvement in cancer. Several studies have shown that LINC01255 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

Additionally, LINC01255 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These studies have shown that LINC01255 is expressed in the brains of individuals with these conditions and that it is involved in the development and progression of these diseases.

Drug Target Potential

The non-protein nature of LINC01255 makes it an attractive drug target. Because it does not encode any protein, it is not likely to have any off-target effects and is less likely to be associated with toxicity. Additionally, because LINC01255 is involved in several diseases, targeting it may have potential therapeutic benefits for these conditions.

One potential approach to targeting LINC01255 is to use small molecules to inhibit its expression. This could be done by targeting the RNA molecule itself, or by targeting the protein it interacts with. Alternatively, LINC01255 could be targeted using antibodies that recognize and bind to specific regions of the protein.

Another approach to targeting LINC01255 is to use CRISPR/Cas9 technology to edit the RNA. This could be done to introduce mutations that render LINC01255 unstable or to remove it altogether.

Conclusion

LINC01255 is a long non-coding RNA that has been shown to be involved in various cellular processes and diseases. Its non-protein nature makes it an attractive drug target, and several studies have shown that it has the potential to be a therapeutic agent for a variety of conditions. Further research is needed to fully understand the role of LINC01255 in disease and to develop effective therapies for its targeting.

Protein Name: Long Intergenic Non-protein Coding RNA 1255

The "LINC01255 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01255 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets